# US 2023/0382930 A1 · Thiadiazolone derivatives and their use as ampk agonists for the treatment of diabetes and related disorders

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2023/0382930 A1
- Document ID: US20230382930A1
- Status: Published application
- Kind: A1
- Application number: 18/028,192
- Filed: 2021-09-30
- Published: 2023-11-30
- Earliest claimed: 2020-10-01
- Assignees: Betagenon Bio AB
- Applicants: Betagenon Bio AB
- Inventors: Thomas EDLUND; Jacob WESTMAN
- Web page: https://patentgrep.com/patent/US20230382930A1

## CPC

- C07F 9/65397: {having the two nitrogen atoms in positions 1 and 3}
- A61P 3/10: for hyperglycaemia, e.g. antidiabetics
- A61P 35/00: Antineoplastic agents
- C07D 285/08: 1,2,4-Thiadiazoles; Hydrogenated 1,2,4-thiadiazoles
- C07F: ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM (metal-containing porphyrins C07D487/22)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)

## Abstract

The invention relates to a compound of formula I, wherein: R1 is as defined in the specification, or a pharmaceutically acceptable salt or solvate thereof, which compounds are useful in the treatment treatment of a disorder or condition ameliorated by the activation of AMPK, particarly as prodrugs.

## Claims

### Claim 1

A compound of formula I,
wherein R1 is selected from the group consisting of —C(O)—C2H4—CO2H and —PO3H2, or a pharmaceutically acceptable salt or solvate thereof.

### Claim 2 (depends on 1)

The compound according to claim 1, wherein the compound of formula I is:
or a pharmaceutically acceptable salt or solvate thereof.

### Claim 3 (depends on 1)

The compound according to claim 1, wherein the compound of formula I is:
or a pharmaceutically acceptable salt or solvate thereof.

### Claim 4 (depends on 1)

The compound according to claim 1, wherein the pharmaceutically acceptable salt is an alkali metal salt, an alkaline earth metal salt or a quaternary ammonium salt of the compound of formula I.

### Claim 5 (depends on 4)

The compound according to claim 4, wherein the pharmaceutically acceptable salt is a sodium or potassium salt of the compound of formula I.

### Claim 6 (depends on 1)

A pharmaceutical formulation comprising a compound according to claim 1, or a pharmaceutically acceptable salt or solvate thereof, and a pharmaceutically acceptable excipient.

### Claim 7 (depends on 6)

The pharmaceutical formulation according to claim 6, wherein the pharmaceutically acceptable excipient is a basic excipient.

### Claim 8 (depends on 6)

The pharmaceutical formulation according to claim 6, wherein the pharmaceutically acceptable excipient is selected from the group consisting of magnesium oxide, sodium hydrogen carbonate, potassium hydrogen carbonate, sodium carbonate, potassium carbonate, magnesium carbonate and calcium carbonate, or any combination thereof.

### Claim 9 (depends on 6)

The pharmaceutical formulation according to claim 6, further comprising an enteric coating.

### Claim 10

(canceled)

### Claim 11

(canceled)

### Claim 12

(canceled)

### Claim 13 (depends on 1)

A method of treating a disorder or condition ameliorated by the activation of AMPK comprising administering a compound according to claim 1, or a pharmaceutically acceptable salt thereof, to a subject in need thereof.

### Claim 14 (depends on 13)

The method according to claim 13, wherein the disorder or condition ameliorated by the activation of AMPK is selected from the group consisting of cardiovascular disease (such as heart failure), diabetic kidney disease, type 2 diabetes, insulin resistance, non-alcoholic fatty liver disease, non-alcoholic steatohepatitis, pain, opioid addiction, obesity, cancer, inflammation (including chronic inflammatory diseases), autoimmune diseases, osteoporosis and intestinal diseases.

### Claim 15 (depends on 13)

The method according to claim 13, wherein the disorder or condition ameliorated by the activation of AMPK is a condition associated with hyperinsulinemia selected from the group consisting of obesity and cardiovascular disease.

### Claim 16 (depends on 13)

The method according to claim 13, wherein the compound is administered orally, subcutaneously or intramuscularly.

### Claim 17 (depends on 1)

A process for preparing a compound according to claim 1, wherein the process comprises:
(i) reacting a compound of formula V,
with a suitable acid or acid anhydride; or
(ii) reacting a compound of formula VI,
with a suitable acid or suitable acid salt.
